NFKB1 and systemic lupus erythematosus: In patients with systemic lupus erythematosus (SLE), serum levels of IL‐38 are significantly elevated and its high levels are associated with the remission of SLE‐related symptoms, including proteinuria, leukocyturia and skin lesions, and it has also been reported that IL‐38 is involved in the progression of SLE by regulating the NF‐κB signaling pathway,57, 58, 59 suggesting that IL‐38 may play a play a protective role in SLE.